5+ day, 6+ hour ago   (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...

1+ week, 11+ hour ago   (359+ words) BiotechDispatch Australian biotech Immuron takes gut health treatment to the US market Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB....

1+ week, 4+ day ago   (338+ words) Prescient Therapeutics has reached an enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December. The Melbourne-based clinical-stage oncology company said…...

2+ week, 6+ day ago   (235+ words) Acrux has appointed physician and biopharmaceutical executive Dr Jolanta Airey as its chief medical officer, strengthening its leadership team as it prepares to advance its female testosterone treatment toward Phase 3 clinical trials in the United States. The Melbourne-based specialty company…...

2+ week, 6+ day ago   (354+ words) Neuren Pharmaceuticals has reached a major milestone in the global commercialisation of trofinetide after the European Commission granted marketing authorisation for DAYBU to treat neurobehavioural symptoms associated with Rett syndrome. The approval makes DAYBU the first and only authorised treatment…...

2+ week, 6+ day ago   (418+ words) Avecho Biotechnology has appointed senior pharmaceutical executive Eve Williamson as a strategic business development consultant, bringing dedicated dealmaking capacity as the company seeks international partners for its CBD TPM soft-gel capsule for insomnia. The appointment comes as Avecho advances its…...